How Novartis is Building Next-Gen Healthcare

Novartis is an innovative medicines company – working every day to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

Expanding radioligand therapy in Texas

Its efforts to create the future of healthcare can be seen with its involvement in new healthcare facilities – such as a new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients. The company plans to create a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas.

This purpose-built site will be the company’s fifth in the US and first manufacturing facility in Texas, marking further progress in the company’s US$23bn US investment.

“RLT has the potential to revolutionise cancer care,” says Vas Narasimhan, CEO of Novartis.

“The addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.”

The Denton facility is set to bolster the local economy by introducing a range of Novartis roles in bioengineering, advanced manufacturing, quality control and operations. With construction kicking off this year, the site is slated to be fully operational by 2028.

“Texas is a leading biotech hub and home to ground-breaking advancements in medicine,” adds Governor Greg Abbott.

“This significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing and more. Working together with innovative global leaders, we will continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the US.”

Precision medicine and global logistics

The new Texas facility strengthens Novartis’s premier RLT manufacturing network, joining established sites in New Jersey, Indiana and California, alongside a recently announced Florida location.

This expansion ensures unrivalled, coast-to-coast capacity for Radioligand Therapy. Because RLT doses are custom-made and highly time-sensitive, this expanded footprint is vital for maintaining Novartis's 99% on-time delivery rate.

Novartis is redefining oncology through RLT, which delivers targeted radiation directly to cancer cells throughout the body.

With one of the industry's deepest pipelines, Novartis is currently researching RLT applications for prostate, breast, lung and pancreatic cancers, among others. This world-class supply chain ensures these life-changing treatments reach patients exactly when they need them.

Advancing research in San Diego

The news of the RLT site comes shortly after the company broke ground on a new, state-of-the-art global Biomedical Research centre in San Diego, California. It is designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients.

Once operational in 2029, the approximately 466,000-square-foot facility is expected to house about 1,000 Novartis employees and integrate seamlessly with Novartis global research sites including Cambridge, Massachusetts and Basel, Switzerland, enabling integrated discovery efforts across regions.

“This new research centre will strengthen our scientific leadership and accelerate the discovery of transformative medicines for patients worldwide, while deepening our connectivity with biotech, academic and technology partners across the region,” says Fiona Marshall, President of Biomedical Research at Novartis.

“Designed to power future drug discovery, with a focus on genetics and human biology in key therapeutic areas such as neuroscience and oncology, it will create a single Novartis research center within one of the world’s premier life sciences ecosystems – accelerating our pipeline from discovery to patients.”

The San Diego research facility is a key pillar of the company’s US$23bn US investment. This includes a new flagship manufacturing hub in North Carolina; the opening of a radioligand therapy manufacturing facility in Carlsbad, California; investments to expand existing facilities in Indiana and New Jersey; and plans to build new RLT manufacturing facilities in Florida and Texas.